Skip to content

Indian firm gets US FDA nod for brain tumors detection test

'TriNetra™-Glio' developed by Datar Cancer Genetics is a form of liquid biopsy which tests cells in the blood from brain tumors which are extremely rare and hard to detect

Image- Datar Cancer Genetics

India’s leading molecular oncology facility, Datar Cancer Genetics has come up with breakthrough 'TriNetra™-Glio', a blood test for diagnosis of inaccessible or inoperable brain tumors.

The company announced that the discovery has gained the attention of the US Food and Drug Administration (FDA), which granted the liquid brain tumor detection test the  'Breakthrough Device Designation.'

This post is for paying subscribers only


Already have an account? Log in